At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 31 enrolled
Drug / intervention
GLPG3970 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of GLPG3970, Administered Orally for 6 Weeks in Adult Subjects With Moderately to Severely Active Ulcerative Colitis
In Brief
A Phase 2 clinical trial evaluating GLPG3970 and Placebo for Ulcerative Colitis. Completed, enrolled 31 participants across 15 sites in 4 countries.
Detailed Summary
The primary objective of this study was to evaluate the effect of GLPG3970 compared to placebo on the signs and symptoms of Ulcerative Colitis (UC) in participants with moderately to severely active UC.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUlcerative Colitis
CountriesGeorgia, Moldova, Poland, Ukraine
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
Enrollment StartOct 2020
First PostedOct 2020
Primary CompletionMay 2021
Study CompletionMay 2021
TodayJul 2026
First PostedOct 8, 2020
Enrollment StartOct 5, 2020
Primary CompletionMay 17, 2021
Study CompletionMay 31, 2021
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 5.7 years ago
Interventions
GLPG3970drug
GLPG3970 powder and solvent for oral solution reconstituted prior to use.
Placebodrug
Placebo powder and solvent for oral solution reconstituted prior to use.